Suppr超能文献

日本1型糖尿病的胰腺移植:过去、现在及未来展望

Pancreas transplantation for type 1 diabetes in Japan: past, present and future prospects.

作者信息

Awata Takuya, Kenmochi Takashi, Tomimaru Yoshito, Eguchi Hidetoshi, Ito Toshinori, Shimoda Masayuki

机构信息

Center for University-wide Education, School of Health and Social Services, Saitama Prefectural University, Saitama, Japan.

The Central Coordination Committee of the Pancreas Transplantation in Japan, Tokyo, Japan.

出版信息

Glob Health Med. 2020 Dec 31;2(6):360-366. doi: 10.35772/ghm.2020.01069.

Abstract

In Japan, the first pancreas transplantation was performed in 1984 from a brain-dead donor; subsequently, however, the concept of brain death became a social issue. Thereafter, the "Organ Transplant Act", which enables brain-dead transplantation, was enacted in 1997, and then revised in 2010 so that donation after brain death became possible only with the consent of the family. Under the recipient selection and registration system developed after the enactment of the "Organ Transplant Act", more than 400 pancreas transplants have been carried out at facilities certified for brain-dead pancreas transplantation in Japan. Of the 410 total cadaveric pancreas transplants performed by the end of 2019, the patient survival and pancreatic and kidney graft survival rates were considered to be comparable to those in the United States and Europe despite the high frequency of marginal donors. Minimally invasive allogenic islet transplantation came to be covered by national health insurance in 2020 following good outcomes of a recent trial. Furthermore, to overcome the serious donor shortage in Japan, development of xenogeneic islet transplantation and regenerative medicine using stem cells is in progress, with xenotransplantation using porcine islets appearing particularly promising.

摘要

在日本,首例胰腺移植于1984年由脑死亡供体完成;然而,随后脑死亡的概念成为一个社会问题。此后,允许脑死亡器官移植的《器官移植法》于1997年颁布,并于2010年修订,以便只有在家属同意的情况下才能进行脑死亡后捐赠。在《器官移植法》颁布后建立的受者选择和登记系统下,日本经认证可进行脑死亡胰腺移植的机构已开展了400多例胰腺移植。截至2019年底进行的410例尸体胰腺移植中,尽管边缘供体的比例较高,但患者生存率以及胰腺和肾脏移植物生存率被认为与美国和欧洲相当。近期一项试验取得良好结果后,微创同种异体胰岛移植于2020年被纳入国民健康保险范围。此外,为克服日本严重的供体短缺问题,利用干细胞的异种胰岛移植和再生医学正在发展,使用猪胰岛的异种移植尤其具有前景。

相似文献

3
Current state of pancreas transplantation in Japan based on the nationwide registry.基于全国登记系统的日本胰腺移植现状
Ann Gastroenterol Surg. 2021 Jan 25;5(4):494-501. doi: 10.1002/ags3.12423. eCollection 2021 Jul.

本文引用的文献

3
Therapies for Type 1 Diabetes: Current Scenario and Future Perspectives.1型糖尿病的治疗:现状与未来展望
Clin Med Insights Endocrinol Diabetes. 2019 May 3;12:1179551419844521. doi: 10.1177/1179551419844521. eCollection 2019.
6
β Cell Replacement Therapy: The Next 10 Years.β 细胞替代治疗:未来 10 年。
Transplantation. 2018 Feb;102(2):215-229. doi: 10.1097/TP.0000000000001937.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验